"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (CD28 ANTIGENS) and CD80 antigens (B7-1 ANTIGEN).
| Descriptor ID |
D019139
|
| MeSH Number(s) |
G12.900
|
| Concept/Terms |
Tumor Escape- Tumor Escape
- Tumor Immune Evasion
- Evasion, Tumor Immune
- Evasions, Tumor Immune
- Immune Evasions, Tumor
- Tumor Immune Evasions
- Immune Evasion, Tumor
- Immune Escape, Tumor
- Tumor Immune Escape
|
Below are MeSH descriptors whose meaning is more general than "Tumor Escape".
Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".
This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 13 | 16 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Escape" by people in Profiles.
-
Is the presence of lung injury in COVID-19 an independent risk factor for secondary lung cancer? Med Hypotheses. 2020 Oct; 143:110074.
-
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1. Clin Cancer Res. 2019 11 15; 25(22):6827-6838.
-
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019 08 15; 79(16):4196-4210.
-
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 08; 560(7718):382-386.
-
CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells. Virchows Arch. 2018 Apr; 472(4):643-651.
-
Quiescent Tissue Stem Cells Evade Immune Surveillance. Immunity. 2018 02 20; 48(2):271-285.e5.
-
PD-1/PD-L1 in disease. Immunotherapy. 2018 02; 10(2):149-160.
-
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018 03; 6(3):255-266.
-
High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol Invest. 2018 Feb; 47(2):169-180.
-
Necroptotic cell death in anti-cancer therapy. Immunol Rev. 2017 11; 280(1):207-219.